>>> US Gapping up

Gapping up
In reaction to earnings/guidance:

WGS +26.6%, GTLS +16.8%, CLS +11.6%, AMKR +9.6%, PHG +9.2%, CDNS +8.6%, SOFI +7.6%, CECO +6.9%, ALKS +6.9%, TFII +6.3%, FLS +5.7%, RNGR +5.6% (also to launch industry's first hybrid double electric workover rigs), RMBS +5.4%, CR +5.3%, PII +4.5%, XPRO +4.4%, SSD +4.2%, NMR +4.2%, CSTM +4.1%, SSTK +4%, GLW +3.9%, AWI +3.7%, BRX +3.4%, DYN +3%, GPK +2.9%, CBRE +2.7%, BYON +2.4%, AZN +2.3%, JBLU +2.3%, INCY +2%, OLN +1.7%, CINF +1.6%, LAD +1.6%, HIG +1.5%, LTM +1.5%, BAND +1.5%, BCS +1.4%, ABG +1.3%

Other news:

SCNI +62.4% (announces new peer-reviewed publication supporting PC111 as a disease-modifying therapy for Pemphigus and SJS/TEN)
SRPT +39.3% (FDA informs co that it recommends co remove its pause and resume shipments of ELEVIDYS for ambulatory individuals)
GTLS +16.5% (Flowserve (FLS) terminates merger with Chart Industries, will receive $266 mln breakup fee after Baker Hughes' (BKR) superior bid)
APLS +16.2% (receives FDA approval for EMPAVELI)
NYXH +9.9% (DREAM pivotal study data published)
CDNS +8.6% (settlement agreement, to pay BIS and the DOJ $140.6 mln)
FLS +5.7% (Flowserve (FLS) terminates merger with Chart Industries, will receive $266 mln breakup fee after Baker Hughes' (BKR) superior bid)
TATT +4.1% (signs $10 mln contract with Israeli defense integrator)
LDI +4.1% (founder and chairman named permanent CEO)
PTCT +4% (FDA approves Sephience to treat PKU)
GL +3.2% (DOJ will not be taking enforcement action)
OLO +2.1% (preliminary merger proxy statement detailing rejected bid)
EYPT +2% (has completed enrollment of its Phase 3 pivotal program with the full enrollment of the LUCIA trial, the second of two identical ongoing pivotal non-inferiority trials evaluating DURAVYU for the treatment of wet age-related macular degeneration)
HESM +1.4% (increases dividend)
UNP +1% (Union Pacific (UNP) will acquire NSC in a stock and cash transaction, implying a value for Norfolk Southern of $320/share)

Analyst comments: